Experimental/Investigational — Denial Risk

Aetna considers macular/foveal translocation experimental and investigational for age-related macular degeneration (AMD) and for all other indications; claims for this procedure are subject to denial.

• Procedures considered experimental/investigational → prior authorization requests would not meet medical necessity and are at high denial risk.

Preferred Therapies Before Surgical Consideration

Anti–vascular endothelial growth factor (anti‑VEGF) intravitreal therapy is the established, guideline-supported first‑line therapy for neovascular (wet) AMD. Surgical translocation has a higher complication rate and worse visual acuity outcomes compared with anti‑VEGF at 5 years in available comparative/observational data, and major guidelines recommend against routine use.

• Preferred first‑line therapy: intravitreal anti‑VEGF agents (e.g., bevacizumab, ranibizumab, aflibercept) per contemporary clinical practice guidelines.
• Clinical concern: higher rates of foveal RPE atrophy, CNV recurrence, proliferative vitreoretinopathy, retinal detachment, and diplopia reported after translocation; worse long‑term VA versus anti‑VEGF in some series.

Potential Clinical Justification Concerns and Documentation Expectations

Translocation procedures may be considered only in highly selected situations (for example, large submacular hemorrhage or patients unresponsive to VEGF inhibitors) and generally only with special arrangements or as part of research; routine use is not recommended. Documented clinical justification should address why anti‑VEGF therapy is not appropriate or has failed.

• Guideline-based expectation: strong recommendation for anti‑VEGF first‑line; limited translocation only after documented failure or contraindication to anti‑VEGF.
• Required documentation (recommended): pre‑ and post‑operative best corrected visual acuity (BCVA), degree of foveal displacement, CNV status (presence/recurrence), and rationale for why standard anti‑VEGF therapy is not suitable.

Step Therapy Expectation

Step‑therapy expectation: intravitreal anti‑VEGF therapy is strongly recommended as first‑line; macular/foveal translocation should be reserved as a later option only after documented failure of, contraindication to, or inability to receive anti‑VEGF therapy.

• Anti‑VEGF must be attempted and documented unless there is a clear contraindication or urgent clinical scenario (e.g., uncontrolled large submacular hemorrhage) that justifies deviation.
• Translocation considered only in select patients and preferably within research settings or special arrangements per guideline recommendations.

Coding / Documentation Note

Coding note: there are no specific CPT or HCPCS codes for macular/foveal translocation. Use appropriate retinal surgery procedure codes if billed; ICD‑10 diagnosis codes commonly associated in documentation include H35.051–H35.059 (retinal neovascularization) and H35.30–H35.3293 (age‑related macular degeneration).

• No dedicated CPT/HCPCS code for macular/foveal translocation — verify coding with billing department.
• ICD‑10 examples to support clinical indication: H35.051–H35.059; H35.30–H35.3293.